1
|
MacCuaig WM, Fouts BL, McNally MW, Grizzle WE, Chuong P, Samykutty A, Mukherjee P, Li M, Jasinski J, Behkam B, McNally LR. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces 2021; 13:49614-49630. [PMID: 34653338 PMCID: PMC9783196 DOI: 10.1021/acsami.1c09379] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Nanoparticles are widely studied as theranostic vehicles for cancer; however, clinical translation has been limited due to poor tumor specificity. Features that maximize tumor uptake remain controversial, particularly when using clinically relevant models. We report a systematic study that assesses two major features for the impact on tumor specificity, i.e., active vs passive targeting and nanoparticle size, to evaluate relative influences in vivo. Active targeting via the V7 peptide is superior to passive targeting for uptake by pancreatic tumors, irrespective of nanoparticle size, observed through in vivo imaging. Size has a secondary effect on uptake for actively targeted nanoparticles in which 26 nm nanoparticles outperform larger 45 and 73 nm nanoparticles. Nanoparticle size had no significant effect on uptake for passively targeted nanoparticles. Results highlight the superiority of active targeting over nanoparticle size for tumor uptake. These findings suggest a framework for optimizing similar nonaggregate nanoparticles for theranostic treatment of recalcitrant cancers.
Collapse
Affiliation(s)
- William M. MacCuaig
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
| | - Benjamin L. Fouts
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
| | - Molly W McNally
- Department of Surgery, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| | - William E. Grizzle
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Phillip Chuong
- Department of Surgery, University of Louisville, Louisville, KY 40202, USA
| | - Abhilash Samykutty
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| | | | - Min Li
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
| | - Jacek Jasinski
- Conn Center Materials Characterization, University of Louisville, Louisville, KY 40202, USA
| | - Bahareh Behkam
- Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, 24061, USA
| | - Lacey R. McNally
- Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Surgery, University of Oklahoma, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, USA
| |
Collapse
|
2
|
Laramie MD, Fouts BL, MacCuaig WM, Buabeng E, Jones MA, Mukherjee P, Behkam B, McNally LR, Henary M. Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Sci Rep 2021; 11:4366. [PMID: 33623069 PMCID: PMC7902650 DOI: 10.1038/s41598-021-83658-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 01/08/2021] [Indexed: 01/31/2023] Open
Abstract
Optoacoustic imaging is a new biomedical imaging technology with clear benefits over traditional optical imaging and ultrasound. While the imaging technology has improved since its initial development, the creation of dedicated contrast agents for optoacoustic imaging has been stagnant. Current exploration of contrast agents has been limited to standard commercial dyes that have already been established in optical imaging applications. While some of these compounds have demonstrated utility in optoacoustic imaging, they are far from optimal and there is a need for contrast agents with tailored optoacoustic properties. The synthesis, encapsulation within tumor targeting silica nanoparticles and applications in in vivo tumor imaging of optoacoustic contrast agents are reported.
Collapse
Affiliation(s)
- Matthew D Laramie
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA
| | - Benjamin L Fouts
- Department of Surgery, Oklahoma Health Science Center, Oklahoma City, 73104, USA
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
| | - William M MacCuaig
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA
| | - Emmanuel Buabeng
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA
- Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA
| | - Meredith A Jones
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA
| | - Priyabrata Mukherjee
- Department of Pathology, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA
| | - Bahareh Behkam
- Department of Mechanical Engineering, Virginia Tech University, Blacksburg, VA, 24061, USA
| | - Lacey R McNally
- Department of Surgery, Oklahoma Health Science Center, Oklahoma City, 73104, USA.
- Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, OK, 73104, USA.
- Department of Biomedical Engineering, University of Oklahoma, Norman, OK, 72073, USA.
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC, 27157, USA.
| | - Maged Henary
- Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
- Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30303, USA.
| |
Collapse
|
3
|
Samykutty A, Grizzle WE, Fouts BL, McNally MW, Chuong P, Thomas A, Chiba A, Otali D, Woloszynska A, Said N, Frederick PJ, Jasinski J, Liu J, McNally LR. Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 2018; 182:114-126. [PMID: 30118979 PMCID: PMC6289590 DOI: 10.1016/j.biomaterials.2018.08.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 07/30/2018] [Accepted: 08/01/2018] [Indexed: 12/12/2022]
Abstract
At the intersection of the newly emerging fields of optoacoustic imaging and theranostic nanomedicine, promising clinical progress can be made in dismal prognosis of ovarian cancer. An acidic pH targeted wormhole mesoporous silica nanoparticle (V7-RUBY) was developed to serve as a novel tumor specific theranostic nanoparticle detectable using multispectral optoacoustic tomographic (MSOT) imaging. We report the synthesis of a small, < 40 nm, biocompatible asymmetric wormhole pore mesoporous silica core particle that has both large loading capacity and favorable release kinetics combined with tumor-specific targeting and gatekeeping. V7-RUBY exploits the acidic tumor microenvironment for tumor-specific targeting and tumor-specific release. In vitro, treatment with V7-RUBY containing either paclitaxel or carboplatin resulted in increased cell death at pH 6.6 in comparison to drug alone (p < 0.0001). In orthotopic ovarian xenograft mouse models, V7-RUBY containing IR780 was specifically detected within the tumor 7X and 4X higher than the liver and >10X higher than in the kidney using both multispectral optoacoustic tomography (MSOT) imaging with secondary confirmation using near infrared fluorescence imaging (p < 0.0004). The V7-RUBY system carrying a cargo of either contrast agent or an anti-neoplastic drug has the potential to become a theranostic nanoparticle which can improve both diagnosis and treatment of ovarian cancer.
Collapse
Affiliation(s)
- Abhilash Samykutty
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - William E Grizzle
- Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
| | - Benjamin L Fouts
- Department of Chemistry, Earlham College, Indianapolis, IN, 27013, USA
| | - Molly W McNally
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Phillip Chuong
- Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Alexandra Thomas
- Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Akiko Chiba
- Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Dennis Otali
- Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
| | - Anna Woloszynska
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Neveen Said
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA
| | - Peter J Frederick
- Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Jacek Jasinski
- Conn Center Materials Characterization, University of Louisville, Louisville, KY 40202, USA
| | - Jie Liu
- Department of Forest Materials, North Carolina State University, Raleigh, NC 27695, USA
| | - Lacey R McNally
- Department of Bioengineering, Wake Forest School of Medicine, Winston-Salem, North Carolina 27013, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27013, USA.
| |
Collapse
|